Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical In Vitro Observations

5 Apr 2023

Abstract excerpt

Background:Treatment of Graves' hyperthyroidism (GH) and Graves' orbitopathy (GO) is far from adequate, and hence, new substances that specifically target the autoantigens in GH/GO are warranted. This study determined the preclinical in vitro efficacy of SYD5115, a novel low-molecular-weight compound that inhibits the thyrotropin receptor (TSH-R). Methods:The TSH-R inhibiting capability of SYD5115 was tested...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuropeptides and Animal Physiology
Share to Ophthalmology and Eye Disorders
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37016815
DOI: 10.1089/thy.2022.0694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical In Vitro ObservationsPMID 37016815Read ↗

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.Semantic proximity Read ↗

Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropin-insensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence.Semantic proximity Read ↗

Expression of Endogenous Putative TSH Binding Protein in Orbit.Semantic proximity Read ↗

The phenotype of Graves' orbitopathy is associated with thyrotropin receptor antibody levels.Semantic proximity Read ↗

Pathogenesis of Graves' orbitopathy: a 2010 update.Semantic proximity Read ↗

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ OrbitopathySemantic proximity Read ↗

A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.Semantic proximity Read ↗

Soluble ecto-domain mutant of thyrotropin (TSH) receptor incapable of binding TSH neutralizes the action of thyroid-stimulating antibodies from Graves' patients.Semantic proximity Read ↗

Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.Semantic proximity Read ↗

[Graves' disease].Semantic proximity Read ↗

TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.Semantic proximity Read ↗

Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.